Condition: Metastatic Colorectal Cancer (mCRC) · Sponsor: QIAGEN Gaithersburg, Inc
To utilize the therascreen KRAS RGQ PCR Kit, as a screening test in Amgen's Phase 3 Clinical Study Protocol 20210081, in order to identify patients with mCRC KRAS G12C mutation positive tumors to be enrolled in the drug clinical trial. Results of the Phase 3 Amgen Study 20210081 will serve as the basis for establishing the clinical performance of the therascreen® KRAS RGQ PCR Kit as a companion diagnostic (CDx) for the identification of patients with metastatic colorectal cancer, who may benefit from treatment with sotorasib.
This description comes directly from the study's public registry record.
Sarah Johnson, Dr. · 0044 07825866041 · sarah.johnson@qiagen.com
Parul Choudhary · Parul.Choudhary@qiagen.com
Always discuss trial participation with your own doctor first.
| QIAGEN Gaithersburg, Inc | Manchester, Manchester, United Kingdom | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06645236